Related articles:

Atara Biotherapeutics Inc.: Atara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights
August 08, 2016
August 8, 2016

Atara Biotherapeutics Inc.: Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights
May 05, 2016
May 5, 2016

Atara Biotherapeutics Inc.: Atara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights
March 03, 2016
March 3, 2016

Atara Biotherapeutics Inc.: Atara Bio Added to the NASDAQ Biotechnology Index
December 18, 2015
December 18, 2015

Atara Biotherapeutics Inc.: Atara Bio Announces Results From the Phase 2 Proof-of-Concept PINTA 745 Clinical Trial for Protein Energy Wasting in Patients With End Stage Renal Disease
December 14, 2015
December 14, 2015

Atara Biotherapeutics Inc.: Atara Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Exclusive License and Research Agreements
October 21, 2015
October 21, 2015

Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2015 Results
August 06, 2015
August 6, 2015

Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces First Quarter 2015 Results
May 07, 2015
May 7, 2015

Atara Biotherapeutics Inc.: Atara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors
March 27, 2015
March 27, 2015

Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2014 Operating Results
February 26, 2015
February 26, 2015

Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Third Quarter 2014 Operating Results
November 12, 2014
November 12, 2014

Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Pricing of Its Initial Public Offering
October 15, 2014
October 15, 2014

Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Immunotherapy Alliance with Memorial Sloan Kettering Cancer Center
September 23, 2014
September 23, 2014

Pin It on Pinterest

Share This